Thrasos Therapeutics is a privately held, clinical-stage biotherapeutics company focused on delivering new solutions for kidney disease. Its lead compound, THR-184, is a proprietary peptide that acts on the BMP/Smad pathway and showed protective effects in preclinical studies; it was safe and well-tolerated in two Phase 1 trials. THR-184 is being evaluated in a 450-patient Phase 2 study to prevent acute kidney injury (AKI) in patients undergoing cardiac surgery across 40 sites in Canada and the United States; the study has passed an interim futility analysis and is expected to reach enrollment this summer. THR-184 has been granted FDA Fast Track designation for this indication. The company plans to use proceeds to complete the ongoing Phase 2 study and to extend development of its core technology into chronic kidney disease (CKD) programs. Thrasos is headquartered in Montreal with a satellite office in Boston. Thrasos is a private, clinical-stage biotherapeutics company focused on discovering and developing targeted therapies for prevention and treatment of kidney disease, including acute kidney injury (AKI) and chronic kidney disease (CKD). Its lead product candidate, THR-184, has shown positive data in preclinical and Phase 1 studies and is intended to protect, repair and restore cell and tissue function in the kidney. Thrasos states its drug candidates have oral activity. The company plans to advance THR-184 through a Phase 2 proof-of-concept clinical program in AKI. The financing announced in the articles will fund progression of the THR-184 program. The company is presented in the article from Montreal and positions AKI as an area of high unmet need with no current drug therapies.

Total raised

$56M

Funding rounds

2

Latest round

Series D

Latest activity

Mar 2015